Streetbeat News

Stock Prices

KYTX

Kyverna Therapeutics is set to present its strategic priorities at the J.P. Morgan Healthcare Conference, focusing on its leadership in autoimmune CAR T therapies. The company is advancing KYV-101 for stiff person syndrome and expanding into broader autoimmune indications with KYV-102. Kyverna aims for a BLA filing by 2026 and has a cash runway into 2027.

Portfolio Pulse from

January 13, 2025 | 12:45 pm

MU

Micron Technology, Inc. is facing a lawsuit for alleged securities law violations. Investors who have incurred losses are encouraged to contact Levi & Korsinsky for potential recovery options.

Portfolio Pulse from

January 13, 2025 | 12:45 pm

M

Macy's has announced that it expects its fourth-quarter net sales to fall slightly below the previously forecasted range of $7.8 billion to $8.0 billion.

Portfolio Pulse from

January 13, 2025 | 12:30 pm

IGPT

IGPT, an ETF with a high expense ratio, is heavily invested in cyclical semiconductor and software stocks, making it volatile and risky. It remains 24.7% below its 2021 peak, indicating potential downside risk despite benefiting from AI evolution. Current valuations are expensive.

Portfolio Pulse from

January 13, 2025 | 12:30 pm

MRNA

Moderna's stock has declined following a disappointing forecast for its Covid-19 vaccine revenue, which is expected to be between $1.5 billion and $2.5 billion in 2025.

Portfolio Pulse from

January 13, 2025 | 12:30 pm

NVDA

Nvidia's stock has seen a significant rise of 171% in 2024 due to increased demand for its AI chips, with a Wall Street analyst predicting a potential price target of $175. The stock is currently around $140.

Portfolio Pulse from

January 13, 2025 | 12:30 pm

MSTR

The article discusses why MicroStrategy's shares should trade at a premium, potentially due to its strategic decisions or market positioning.

Portfolio Pulse from

January 13, 2025 | 12:30 pm

PLTR

Cathie Wood, CEO of Ark Investment Management, sold $17 million worth of Palantir stock in the first week of January 2025, raising questions about the reasons behind this decision.

Portfolio Pulse from

January 13, 2025 | 12:30 pm

RDCM

Radcom (RDCM) experienced a 10.5% surge in share price with above-average trading volume. However, the trend in earnings estimate revisions does not indicate further strength.

Portfolio Pulse from

January 13, 2025 | 12:30 pm